Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 471

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient

Open access
Sperduto, Paul W., Mesko, Shane, Li, Jing, Cagney, Daniel, Aizer, Ayal, Lin, Nancy U., Nesbit, Eric, Kruser, Tim J., Chan, Jason, Braunstein, Steve, Lee, Jessica, Kirkpatrick, John P., Breen, Will, Brown, Paul D., Shi, Diana, Shih, Helen A., Soliman, Hany, Sahgal, Arjun, Shanley, Ryan, Sperduto, William A., Lou, Emil, Everett, Ashlyn, Boggs, Drexell H., Masucci, Laura, Roberge, David, Remick, Jill, Plichta, Kristin, Buatti, John M., Jain, Supriya, Gaspar, Laurie E., Wu, Cheng-Chia, Wang, Tony J.C., Bryant, John, Chuong, Michael, An, Yi, Chiang, Veronica, Nakano, Toshimichi, Aoyama, Hidefumi, Mehta, Minesh P.·2020·Journal of Clinical Oncology

Abstract

PURPOSE: Conventional wisdom has rendered patients with brain metastases ineligible for clinical trials for fear that poor survival could mask the benefit of otherwise promising treatments. Our group previously published the diagnosis-specific Graded Prognostic Assessment (GPA). Updates with larger contemporary cohorts using molecular markers and newly identified prognostic factors have been published. The purposes of this work are to present all the updated indices in a single report to guide treatment choice, stratify research, and define an eligibility quotient to expand eligibility. METHODS: A multi-institutional database of 6,984 patients with newly diagnosed brain metastases underwent multivariable analyses of prognostic factors and treatments associated with survival for each primary site. Significant factors were used to define the updated GPA. GPAs of 4.0 and 0.0 correlate with the best and worst prognoses, respectively. RESULTS: Significant prognostic factors varied by diagnosis and new prognostic factors were identified. Those factors were incorporated into the updated GPA with robust separation ( P < .01) between subgroups. Survival has improved, but varies widely by GPA for patients with non–small-cell lung, breast, melanoma, GI, and renal cancer with brain metastases from 7-47 months, 3-36 months, 5-34 months, 3-17 months, and 4-35 months, respectively. CONCLUSION: Median survival varies widely and our ability to estimate survival for patients with brain metastases has improved. The updated GPA (available free at brainmetgpa.com) provides an accurate tool with which to estimate survival, individualize treatment, and stratify clinical trials. Instead of excluding patients with brain metastases, enrollment should be encouraged and those trials should be stratified by the GPA to ensure those trials make appropriate comparisons. Furthermore, we recommend the expansion of eligibility to allow for the enrollment of patients with previously treated brain metastases who have a 50% or greater probability of an additional year of survival (eligibility quotient > 0.50).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.20.01255

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Cited by

See all 471

Metadata

Authors
Sperduto, P. W., Mesko, S., Li, J., Cagney, D., Aizer, A., Lin, N. U., Nesbit, E., Kruser, T. J., Chan, J., Braunstein, S., Lee, J., Kirkpatrick, J. P., Breen, W., Brown, P. D., Shi, D., Shih, H. A., Soliman, H., Sahgal, A., Shanley, R., Sperduto, W. A., Lou, E., Everett, A., Boggs, D. H., Masucci, L., Roberge, D., Remick, J., Plichta, K., Buatti, J. M., Jain, S., Gaspar, L. E., Wu, C.-C., Wang, T. J. C., Bryant, J., Chuong, M., An, Y., Chiang, V., Nakano, T., Aoyama, H., & Mehta, M. P.
Venue
Journal of Clinical Oncology
Published
2020-11-10
Volume
38
Issue
32
Pages
3773-3784
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W3086164260
Cited by
471
References
40
FWCI
26.97
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient. https://app.cochat.ai/papers/10.1200/jco.20.01255
The paper
Sperduto, P. W., Mesko, S., Li, J., Cagney, D., Aizer, A., Lin, N. U., Nesbit, E., Kruser, T. J., Chan, J., Braunstein, S., Lee, J., Kirkpatrick, J. P., Breen, W., Brown, P. D., Shi, D., Shih, H. A., Soliman, H., Sahgal, A., Shanley, R., . . . Mehta, M. P. (2020). Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient. Journal of Clinical Oncology. https://doi.org/10.1200/jco.20.01255

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.